Welcome to our dedicated page for Scilex Holding Company SEC filings (Ticker: SCLXW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Scilex Holding Company SEC filings page for the warrant symbol SCLXW provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Scilex’s common stock (SCLX) and its warrants to purchase common stock at an exercise price of $402.50 per share (SCLXW) are listed on The Nasdaq Stock Market LLC, and the company identifies itself as an emerging growth company in its reports.
Through forms such as Form 10-K, Form 10-Q, and Form S-1, Scilex describes its business of acquiring, developing, and commercializing non-opioid pain management products, including commercial products ZTlido ae, ELYXYB ae, and Gloperba ae, and product candidates SP-102, SP-103, and SP-104. The registration statement on Form S-1 specifically addresses aspects of the company’s warrants and related securities offerings.
Current reports on Form 8-K give detail on material events that may be relevant to SCLXW holders, such as warrant exchange agreements, new warrant issuances, equity lines of credit, and options to repurchase previously issued warrants. For example, Scilex has reported a Common Stock Purchase Agreement with an institutional investor, Warrant Exchange Agreements that modify existing warrant terms, and an option agreement with Oramed Pharmaceuticals Inc. to repurchase penny warrants. Other 8-K filings discuss Semnur Pharmaceuticals, Inc.’s merger agreement with Denali Capital Acquisition Corp. and changes in executive leadership.
These filings also disclose Scilex’s collaborations and licensing arrangements, including a worldwide exclusive license from Datavault AI Inc. for AI-driven tokenization technology in biotech and biopharma, and strategic investments in Datavault AI. Such agreements can influence Scilex’s long-term business model and potential revenue sources, and are documented in detail in the underlying exhibits and narrative sections.
On Stock Titan, investors can use AI-powered tools to review Scilex’s 10-K annual reports, 10-Q quarterly reports, S-1 registration statements, and 8-K current reports. AI-generated summaries help explain complex capital structure terms for SCLXW, highlight key risk factors and business descriptions, and surface notable items such as warrant terms, exchange ratios, and major financing arrangements, while real-time updates ensure new EDGAR filings are reflected promptly.
Scilex Holding Company entered into a Warrant Agreement with Oramed Pharmaceuticals under which Oramed deferred an amortization payment on Scilex’s Tranche B senior secured convertible note that had been scheduled for October 1, 2025. In exchange, Scilex agreed to issue Oramed a new warrant to purchase 100,000 shares of common stock at an initial exercise price of $20.00 per share, called the February 2026 Warrant. The deferred amortization payment was ultimately made in November 2025, and the warrant is immediately exercisable and expires on December 13, 2029.
Scilex committed to file a registration statement to register the resale by Oramed of the shares issuable upon exercise, or to include them in another Form S-3. The warrant includes price-adjustment mechanisms, subject to a floor of $8.22 per share, a beneficial ownership cap initially at 4.99% (optionally adjustable up to 9.99% with notice), cashless exercise if no effective registration is available, and change-of-control protections allowing Oramed to require cash repurchase based on Black Scholes value.
Scilex Holding Company’s Schedule 13G/A Amendment No. 4 reports that Oramed Pharmaceuticals Inc. beneficially owns 437,510 shares of Scilex common stock, representing 4.9% of the outstanding class. These shares are issuable upon exercise of warrants and conversion of convertible notes that are exercisable within 60 days.
The ownership percentage is calculated using 8,491,267 Scilex common shares outstanding as of December 5, 2025, plus the 437,510 shares underlying Oramed’s instruments. Oramed states the securities were not acquired and are not held for the purpose of changing or influencing control of Scilex.
Scilex Holding Company announced that its board of directors has revoked a previously declared stock dividend of 5,000,000 shares of Series 1 Mandatory Exchangeable Preferred Stock. This preferred stock had been authorized but no shares were ever issued.
In connection with the revocation, Scilex filed a Certificate of Elimination in Delaware, which became effective upon filing. This action eliminated the Series 1 designation and returned the 5,000,000 preferred shares to the company’s pool of undesignated preferred stock, effectively ending the special series that had been created for the contemplated dividend.
Scilex Holding Company entered into a financing and equity transaction with Quantum Scan Holdings, Inc. (Q Scan). Scilex loaned Q Scan
Separately, Scilex agreed in a common stock purchase agreement to buy an additional 193,021,436 Q Scan shares for an aggregate price of approximately
Scilex Holding Company disclosed changes in executive status and debtor-in-possession (DIP) financing arrangements. Dr. Ji is referenced in connection with a decision to resign as Chief Executive Officer and President to focus on Semnur, while the filing also states his compensation was not changed upon appointment as CEO and President and that he entered an indemnification agreement. The filing compares terms of a Junior DIP Loan (higher interest and fees: 14.0% vs 12.0%, maturity 5 vs 3 months, commitment/funding fees 2.5% vs 1.0%, exit fee 7.0% vs 2.0%). It describes a $100,000,000 Replacement DIP Facility provided by Oramed Pharmaceuticals, which refinanced the Senior DIP and included milestones and a lender credit-bid right for collateral (including equity interests). The Purchase Price for certain assets included a cash payment of $10,000,000 and assumption of approximately $12.25 million in legal fees; Sorrento retained 54,777 common shares in abeyance. A Pay-Off Letter would terminate the Junior DIP Loan Agreement and related security agreements upon Closing.
Oramed Pharmaceuticals Inc. filed an amendment to Schedule 13G disclosing beneficial ownership of 764,277 shares of Scilex Holding Co. common stock, representing 9.9% of the class. The filing clarifies that 762,277 of these shares are issuable upon exercise of warrants exercisable within 60 days of the filing date and that the total percent calculation used 6,955,697 outstanding shares reported by the issuer. Oramed reports sole voting and dispositive power over all 764,277 shares. The filing states the holdings were not acquired to change or influence control.
Scilex Holding Company is a revenue-generating, non-opioid pain-management company that commercializes ZTlido, ELYXYB and GLOPERBA and is developing SP-102, SP-103 and SP-104. For the quarter ended June 30, 2025 the Company reported net revenue of $9.9 million and for the six months a net loss of $70.1 million, driven by an operating loss of $48.4 million and large non-cash fair value and derivative losses.
Balance sheet highlights show $4.1 million in cash, total assets of $83.8 million, total liabilities of $332.7 million and total stockholders' deficit of $(249.0) million. Management disclosed substantial doubt about the Company’s ability to continue as a going concern for one year and identified a negative working capital position of $272.3 million. Material items include a $43.8 million deemed dividend from a 1-for-35 reverse split that increased loss attributable to common shareholders, $20.3 million of derivative warrant liabilities, significant accrued rebates and fees of $192.9 million, and concentrated customer exposure (four customers represented 99% of revenue).